Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PARG | Q86W56 | 3/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680469 | 0.89 | CYP1A2 (0.54) | CYP1A2CRHR1CRHR2ALDH1A1NPC1 | |
| SCHEMBL12434372 | 0.85 | PARG (0.54) | CYP1A2CRHR1CRHR2ALDH1A1NPC1 | |
| SCHEMBL11247925 | 0.83 | BRD4 (0.52) | CYP1A2KMT2APARG | |
| Hydrochloric Acid SCHEMBL2264513 | 0.81 | CRHR1 (0.47) | CYP1A2CRHR1CRHR2ALDH1A1NPC1 | |
| SCHEMBL11949817 | 0.76 | CRHR1 (0.51) | CRHR1CRHR2ALDH1A1TSHRMEN1 | |
| SCHEMBL3633938 | 0.75 | OPRL1 (0.61) | ALDH1A1 | |
| SCHEMBL13075558 | 0.75 | CYP1A2 (0.49) | CYP1A2ALDH1A1NPC1TSHRMEN1 | |
| Hydrochloric Acid SCHEMBL11512078 | 0.74 | SLC6A2 (0.45) | CYP1A2ALDH1A1NPC1TSHRMEN1 | |
| SCHEMBL25720568 | 0.74 | OPRD1 (0.48) | CRHR1CRHR2ALDH1A1 | |
| SCHEMBL2986176 | 0.74 | DDB1 (0.54) | PIK3CAPRKDCSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | CYP1A2 1172/4885PIK3CA 2967/4885PRKDC 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.